We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Analysts See More FDA Concerns With Constipation Drugs Post-CRL
Analysts See More FDA Concerns With Constipation Drugs Post-CRL
August 3, 2012
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say.